Bio-Thera(SH:688177)2025-02-25 08:25Financial Performance - Total revenue for 2024 reached RMB 743.17 million, a year-on-year increase of 5.44%[5] - Net profit attributable to the parent company was RMB -508.84 million, with a net profit excluding non-recurring gains and losses of RMB -554.15 million[5] - Basic earnings per share were RMB -1.23, and the weighted average return on net assets was -53.10%[5] - Operating loss increased by RMB 117.13 million compared to the same period last year, primarily due to increased operating costs and sales expenses[6] Assets and Equity - Total assets at the end of the reporting period were RMB 2,199.93 million, a decrease of 3.81% from the beginning of the year[5] - Equity attributable to the parent company decreased by 41.96% to RMB 703.85 million, with a corresponding decrease in net asset per share to RMB 1.70, down 41.98%[6] Research and Development - R&D expenses amounted to RMB 776.38 million, a 1.01% increase from RMB 768.64 million in the previous year, reflecting the company's commitment to drug development[6] Business Expansion - The company is expanding its overseas supply business for certain products, although revenue growth from these efforts remains limited[6] Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be confirmed in the annual report[8] - Investors are advised to be cautious as the reported net profit and other key indicators may differ from those in the annual report[8]